Skip to main content
. 2022 Mar 11;4:785698. doi: 10.3389/fgeed.2022.785698

FIGURE 5.

FIGURE 5

Gene targeting of adult FIX KO mice with gene-targeting strategy coupled to SaCas9. (A) Experimental plan. FIX KO adult mice were injected at 2 months of age (P60) with 1.0E11 vg/mouse of AAV8-SaCas9 and 5.0E11 vg/mouse of AAV8-donor-hFIX. Blood was collected 1 and 2 months after treatment. (B) Plasma hFIX levels in mouse transduced with SaCas9 and donor-hFIX at post-natal (P) day 2 (n = 15) and 60 (n = 8). hFIX concentration obtained from blood samples at months 1, 2, and 4 (P2 treatment) and 2, 3 and 4 months (P60 treatment). 5,000 ng/ml corresponds to the normal FIX plasma levels in healthy individuals in the human population. (C) Tail-bleeding assay. Bleeding time was evaluated in treated adult FIX KO mice (n = 8) and compared to untreated WT (n = 10) and FIX KO (n = 8) mice. Data are shown as mean ± SEM and statistically analyzed by one-way ANOVA with Tukey’s multiple comparison test.